targeted-therapy
(4)
Albert Luderer
He spent thirty years turning lab science into products doctors actually use. Now he is betting that a synthetic peptide can beat the antibody at its own game.
Steven Everett
Steven Everett is a biotechnology executive and cancer scientist who founded MaveriX Oncology in Palo Alto, California, where he serves as President and CEO. With a background rooted in more than two decades of cancer research at the University of Oxford, University of Dundee and UCSF, he has built his career around a single idea: making cancer drugs that switch on only inside tumors. At MaveriX he is developing conditionally activated small-molecule therapeutics that exploit hydroxylase biology in the tumor immune microenvironment, aiming to hit cancer hard while sparing healthy tissue.
Joel Barrish
Joel Barrish is the President and CEO of Avilar Therapeutics, a Waltham, Massachusetts-based biotechnology company pioneering extracellular protein degradation. A medicinal chemist by training with a Ph.D. from Columbia University, Barrish spent 28 years at Bristol Myers Squibb rising to VP and Global Head of Discovery Chemistry, co-inventing blockbuster drugs including SPRYCEL (dasatinib) for leukemia. After stints as CSO at Achillion Pharmaceuticals and co-founder/President at Jnana Therapeutics, he founded Avilar in 2019 to build the ATAC and MTAC platforms - bifunctional molecules that hijack the body's own cellular recycling machinery to degrade disease-causing proteins outside the cell, a class of targets previously undruggable. Avilar has raised $75 million in total seed financing.
Josh Bilenker
Josh Bilenker is the CEO and co-founder of Treeline Biosciences, a Watertown, Massachusetts biotech building precision oncology medicines. A physician by training who once reviewed cancer drugs at the FDA, he founded Loxo Oncology in 2013 and took a tumor-agnostic, genomics-first approach he likened to 'moneyball' target selection. Loxo produced three FDA-approved medicines and was bought by Eli Lilly for roughly $8 billion in 2019. In 2021 he started Treeline with former Novartis research head Jeff Engelman, and in 2026 the company agreed to merge with Standard BioTools to go public as 'Treeline Biosciences' (Nasdaq: TRLN).